3 biotech stocks battle the ‘Dendreon Effect’
August 18, 2011 at 19:49 PM EDT
Dendreon Corp.’s tepid sales report has not only chilled trading in the company’s once-hot stock but has also managed to frost investors in three other biotechs: Savient Pharmaceuticals, Human Genome Sciences and InterMune Inc.